Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Case report

Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma

Authors: Takaaki Inoue, Hidefumi Kinoshita, Yoshihiro Komai, Takashi Kawabata, Gen Kawa, Yoshiko Uemura, Tadashi Matsuda

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

We report two cases of gastrointestinal perforation (GIP) after radiotherapy in patients receiving tyrosine kinase inhibitor (TKI) for advanced renal cell carcinoma (RCC). Case 1 was a 61-year-old woman with lung metastases after a radical nephrectomy for a right RCC (cT3aN0M0) treated with interferon-alpha (OIF, 5 MIU, three times per week). She developed lytic metastases of the left femur and the left acetabulum. She was treated with palliative radiotherapy to the metastatic portion (3 Gy × 10 fractions), and 400 mg sorafenib twice per day plus continuing interferon alpha. She experienced sudden left lower abdominal pain after four weeks of treatment, and was diagnosed with a perforation of the sigmoid colon with fecal peritonitis. Case 2 was a 48-year-old man with lung, lymph node, and bone metastases after a radical nephrectomy for a right RCC (cT2N0M0), and was treated with 400 mg sorafenib twice per day. He developed lytic bone metastases of the lumbar vertebrae, which was treated with palliative radiotherapy to L2-4 (3 Gy × 10 fractions). He experienced sudden abdominal pain after two months of radiation treatment, and was diagnosed with a perforation of the sigmoid colon with fecal peritonitis. These cases underwent radiotherapy, and therefore this may be related to the radiosensitivity of TKI.
Appendix
Available only for authorised users
Literature
1.
go back to reference Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007, 356: 125-134. 10.1056/NEJMoa060655.CrossRefPubMed Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007, 356: 125-134. 10.1056/NEJMoa060655.CrossRefPubMed
2.
go back to reference Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356: 115-124. 10.1056/NEJMoa065044.CrossRefPubMed Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007, 356: 115-124. 10.1056/NEJMoa065044.CrossRefPubMed
3.
go back to reference Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002, 20: 289-296. 10.1200/JCO.20.1.289.CrossRefPubMed Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002, 20: 289-296. 10.1200/JCO.20.1.289.CrossRefPubMed
4.
go back to reference Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016/S0140-6736(06)69446-4.CrossRefPubMed Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016/S0140-6736(06)69446-4.CrossRefPubMed
5.
go back to reference The third interim analysis report (unresectable/metastatic renal cell carcinoma) of the postmarketing. 2011, Surveillance Review of Sorafenib The third interim analysis report (unresectable/metastatic renal cell carcinoma) of the postmarketing. 2011, Surveillance Review of Sorafenib
6.
go back to reference Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase trial. J Clin Oncol. 2010, 28: 1061-1068. 10.1200/JCO.2009.23.9764.CrossRefPubMed Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase trial. J Clin Oncol. 2010, 28: 1061-1068. 10.1200/JCO.2009.23.9764.CrossRefPubMed
7.
go back to reference Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Phase III trial of Bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010, 28: 2137-2143. 10.1200/JCO.2009.26.5561.PubMedCentralCrossRefPubMed Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Phase III trial of Bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010, 28: 2137-2143. 10.1200/JCO.2009.26.5561.PubMedCentralCrossRefPubMed
8.
go back to reference Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HO, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet. 2011, 378: 1931-1939. 10.1016/S0140-6736(11)61613-9.CrossRefPubMed Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HO, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet. 2011, 378: 1931-1939. 10.1016/S0140-6736(11)61613-9.CrossRefPubMed
9.
go back to reference Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KL, Niethammer AG, Kim S, Rixe O: Multicenter, phase II study of Axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011, 17: 7462-7469. 10.1158/1078-0432.CCR-11-0534.CrossRefPubMed Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KL, Niethammer AG, Kim S, Rixe O: Multicenter, phase II study of Axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011, 17: 7462-7469. 10.1158/1078-0432.CCR-11-0534.CrossRefPubMed
10.
go back to reference Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group: M: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372: 449-456. 10.1016/S0140-6736(08)61039-9.CrossRefPubMed Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, RECORD-1 Study Group: M: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008, 372: 449-456. 10.1016/S0140-6736(08)61039-9.CrossRefPubMed
11.
go back to reference Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007, 356: 2271-2281. 10.1056/NEJMoa066838.CrossRefPubMed Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007, 356: 2271-2281. 10.1056/NEJMoa066838.CrossRefPubMed
12.
go back to reference Langenberg MH, Witteveen PO, Roodhart J, Lolkema MP, Verheul HM, Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JH, Voest EE: Phase 1 evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol. 2011, 11: 2508-15.CrossRef Langenberg MH, Witteveen PO, Roodhart J, Lolkema MP, Verheul HM, Mergui-Roelvink M, Brendel E, Krätzschmar J, Loembé B, Nol-Boekel A, Christensen O, Schellens JH, Voest EE: Phase 1 evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol. 2011, 11: 2508-15.CrossRef
13.
go back to reference Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD: Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009, 27: 83-87. 10.1007/s10637-008-9146-z.CrossRefPubMed Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD: Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009, 27: 83-87. 10.1007/s10637-008-9146-z.CrossRefPubMed
14.
go back to reference Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LKA: Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol. 2008, 14: 2405-2406.CrossRef Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LKA: Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol. 2008, 14: 2405-2406.CrossRef
15.
go back to reference Hoshino Y, Hasegawa H, Ishii Y, Endo T, Ochiai H, Okabayashi K, Kaneko G, Mikami S, Mukai M, Oya M, Kitagawa Y: Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.I. J Clin Oncol. 2011, Sep 17. [Epub ahead of print] Hoshino Y, Hasegawa H, Ishii Y, Endo T, Ochiai H, Okabayashi K, Kaneko G, Mikami S, Mukai M, Oya M, Kitagawa Y: Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma.I. J Clin Oncol. 2011, Sep 17. [Epub ahead of print]
16.
go back to reference Eifel PJ, Levenback C, Wharton JT, Oswald MJ: Time, course, and incidence of late complications in patients treated with radiation therapy for FIGO stage1B carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995, 32: 1289-1300. 10.1016/0360-3016(95)00118-I.CrossRefPubMed Eifel PJ, Levenback C, Wharton JT, Oswald MJ: Time, course, and incidence of late complications in patients treated with radiation therapy for FIGO stage1B carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995, 32: 1289-1300. 10.1016/0360-3016(95)00118-I.CrossRefPubMed
17.
go back to reference Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS: Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer?. Cancer J Sci. 1999, 5: 242- Willett CG, Goldberg S, Shellito PC, Grossbard M, Clark J, Fung C, Proulx G, Daly M, Kaufman DS: Does postoperative irradiation play a role in the adjuvant therapy of stage T4 colon cancer?. Cancer J Sci. 1999, 5: 242-
18.
go back to reference Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Biol Phys. 1991, 21: 109-122.CrossRef Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Biol Phys. 1991, 21: 109-122.CrossRef
19.
go back to reference O’Reilly MS: The interaction of radiation therapy and antiangiogenic therapy. Cancer J. 2008, 14: 207-213. 10.1097/PPO.0b013e3181836af3.CrossRefPubMed O’Reilly MS: The interaction of radiation therapy and antiangiogenic therapy. Cancer J. 2008, 14: 207-213. 10.1097/PPO.0b013e3181836af3.CrossRefPubMed
20.
go back to reference Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Weichselbaum RR: Blockade of vascular endothelial growth factor stress response increase the antitumor effects of ionizing radiation. Cancer Res. 1999, 59: 3374-3378.PubMed Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Weichselbaum RR: Blockade of vascular endothelial growth factor stress response increase the antitumor effects of ionizing radiation. Cancer Res. 1999, 59: 3374-3378.PubMed
21.
go back to reference Wachsberger P, Burd R, Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003, 9: 1957-1971.PubMed Wachsberger P, Burd R, Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003, 9: 1957-1971.PubMed
Metadata
Title
Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma
Authors
Takaaki Inoue
Hidefumi Kinoshita
Yoshihiro Komai
Takashi Kawabata
Gen Kawa
Yoshiko Uemura
Tadashi Matsuda
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-167

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue